Piribedil (Standard)

Piribedil (Standard) is the analytical standard of Piribedil. This product is intended for research and analytical applications. Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM) . Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers[1][2][3][4].

Product Specifications

CAS Number

[3605-01-4]

UNSPSC

12352005

Target

Adrenergic Receptor; Dopamine Receptor; Histone Methyltransferase; Reference Standards

Type

Reference Standards

Related Pathways

Epigenetics; GPCR/G Protein; Neuronal Signaling; Others

Field of Research

Cancer; Endocrinology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/piribedil-standard.html

Smiles

C1(N2CCN(CC3=CC=C(OCO4)C4=C3)CC2)=NC=CC=N1

Molecular Formula

C16H18N4O2

Molecular Weight

298.34

References & Citations

[1]Sweet RD, et al. Piribedil, a dopamine agonist, in Parkinson's disease. Clin Pharmacol Ther. 1974 Dec;16 (6) :1077-82. |[2]Gerlach M, et al. The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α (2) adrenergic mechanisms. J Neural Transm (Vienna) . 2013 Jan;120 (1) :31-6. |[3]Smith LA, Tet al. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord. 2002 Sep;17 (5) :887-901.|[4]Xiong Zhang, et al. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis. Cancer Lett. 2018 Sep 1;431:150-160.